See more : Forth Corporation Public Company Limited (FORTH.BK) Income Statement Analysis – Financial Results
Complete financial analysis of iCAD, Inc. (ICAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iCAD, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Minor International PCL (8MI.SG) Income Statement Analysis – Financial Results
- VK Company Limited (VKCO.IL) Income Statement Analysis – Financial Results
- Storage Computer Corporation (SOSO) Income Statement Analysis – Financial Results
- Topower Co., Ltd. (3226.TWO) Income Statement Analysis – Financial Results
- Appia Rare Earths & Uranium Corp. (APAAF) Income Statement Analysis – Financial Results
iCAD, Inc. (ICAD)
About iCAD, Inc.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.32M | 27.94M | 33.64M | 29.70M | 31.34M | 25.62M | 28.10M | 26.34M | 41.55M | 43.92M | 33.07M | 28.28M | 28.65M | 24.58M | 28.11M | 37.49M | 26.61M | 19.72M | 19.77M | 23.31M | 6.52M | 5.00M | 4.84M | 7.79M | 6.70M | 5.30M | 7.90M | 11.30M | 20.60M | 24.40M | 20.60M | 23.00M | 11.90M | 21.70M | 18.40M | 11.20M | 2.70M |
| Cost of Revenue | 2.78M | 8.13M | 9.40M | 8.34M | 7.11M | 6.19M | 9.93M | 7.82M | 12.20M | 12.70M | 9.98M | 8.24M | 8.63M | 3.15M | 4.62M | 6.18M | 5.26M | 4.29M | 4.64M | 6.53M | 2.94M | 5.16M | 3.94M | 5.27M | 4.50M | 3.40M | 4.90M | 7.10M | 12.00M | 13.50M | 11.70M | 10.40M | 6.90M | 12.10M | 12.10M | 7.60M | 7.10M |
| Gross Profit | 14.54M | 19.81M | 24.24M | 21.35M | 24.23M | 19.43M | 18.18M | 18.52M | 29.35M | 31.23M | 23.09M | 20.03M | 20.03M | 21.43M | 23.49M | 31.32M | 21.36M | 15.43M | 15.13M | 16.78M | 3.58M | -161.46K | 898.89K | 2.52M | 2.20M | 1.90M | 3.00M | 4.20M | 8.60M | 10.90M | 8.90M | 12.60M | 5.00M | 9.60M | 6.30M | 3.60M | -4.40M |
| Gross Profit Ratio | 83.94% | 70.90% | 72.07% | 71.90% | 77.30% | 75.84% | 64.68% | 70.31% | 70.63% | 71.09% | 69.81% | 70.84% | 69.90% | 87.20% | 83.56% | 83.53% | 80.25% | 78.24% | 76.55% | 71.97% | 54.88% | -3.23% | 18.59% | 32.38% | 32.84% | 35.85% | 37.97% | 37.17% | 41.75% | 44.67% | 43.20% | 54.78% | 42.02% | 44.24% | 34.24% | 32.14% | -162.96% |
| Research & Development | 5.16M | 8.59M | 9.19M | 8.11M | 9.27M | 9.45M | 9.33M | 9.52M | 9.16M | 8.16M | 7.69M | 7.77M | 10.79M | 6.60M | 7.22M | 7.12M | 4.50M | 5.26M | 4.79M | 4.83M | 2.38M | 1.63M | 751.47K | 709.60K | 800.00K | 1.10M | 1.40M | 2.40M | 2.80M | 2.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.32M | 11.23M | 10.41M | 9.12M | 7.44M | 9.12M | 7.88M | 7.68M | 8.79M | 8.04M | 6.74M | 6.97M | 10.08M | 9.92M | 7.35M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.74M | 13.69M | 15.14M | 13.31M | 13.63M | 8.69M | 10.50M | 10.18M | 12.40M | 12.47M | 10.43M | 10.71M | 13.68M | 11.49M | 11.04M | 11.96M | 10.78M | 9.23M | 8.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.06M | 24.93M | 25.54M | 22.43M | 21.08M | 17.81M | 18.38M | 17.85M | 21.19M | 20.51M | 17.17M | 17.67M | 23.76M | 21.40M | 18.39M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 5.10M | 8.00M | 7.20M | 8.80M | 9.80M | 7.70M | 7.90M | 0.00 |
| Other Expenses | 0.00 | 224.00K | 240.00K | 199.00K | 276.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| Operating Expenses | 22.23M | 33.74M | 34.98M | 30.74M | 30.62M | 27.56M | 28.16M | 28.49M | 31.99M | 30.41M | 24.86M | 25.44M | 30.39M | 28.00M | 25.61M | 26.55M | 22.46M | 21.87M | 19.89M | 17.04M | 11.66M | 9.21M | 3.44M | 4.22M | 4.40M | 4.80M | 6.10M | 9.60M | 10.80M | 9.60M | 9.30M | 8.40M | 9.50M | 11.80M | 9.50M | 8.50M | 500.00K |
| Cost & Expenses | 25.01M | 41.87M | 44.37M | 39.09M | 37.74M | 33.75M | 38.09M | 36.31M | 44.19M | 43.11M | 34.84M | 33.69M | 39.02M | 31.15M | 30.23M | 32.73M | 27.72M | 26.16M | 24.52M | 23.58M | 14.60M | 14.37M | 7.38M | 9.49M | 8.90M | 8.20M | 11.00M | 16.70M | 22.80M | 23.10M | 21.00M | 18.80M | 16.40M | 23.90M | 21.60M | 16.10M | 7.60M |
| Interest Income | 729.00K | 213.00K | 15.00K | 97.00K | 344.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | 24.00K | 73.27K | 119.10K | 106.03K | 74.15K | 102.96K | 127.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.00K | 10.00K | 141.00K | 476.00K | 784.00K | 504.00K | 124.00K | 63.00K | 650.00K | 2.64M | 3.28M | 3.42M | 419.00K | 269.00 | 9.33K | 280.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 409.00K | 521.00K | 557.00K | 578.00K | 673.00K | 708.00K | 1.49M | 2.31M | 3.35M | 3.53M | 2.43M | 2.80M | 3.17M | 1.64M | 1.92M | 1.84M | 1.70M | 1.66M | 1.63M | 1.34M | 667.89K | 389.88K | 486.14K | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| EBITDA | -6.57M | -9.50M | -10.55M | -16.52M | -12.05M | -7.31M | -12.66M | -7.67M | -28.43M | 4.34M | -1.77M | -3.12M | -34.42M | -4.58M | -80.66K | 6.71M | 598.07K | -4.67M | -3.00M | 1.07M | -7.42M | -8.98M | -2.05M | -1.07M | -1.60M | -2.20M | -1.80M | -3.20M | -200.00K | 2.90M | 900.00K | 5.40M | -3.80M | -200.00K | -1.40M | -4.30M | -4.40M |
| EBITDA Ratio | -37.91% | -47.38% | -30.20% | -54.48% | -38.45% | -30.30% | -30.16% | -29.06% | 1.76% | 9.97% | 2.04% | -9.13% | -25.02% | -19.76% | -7.55% | 17.62% | 2.25% | -24.21% | -15.79% | 4.60% | -113.73% | -179.60% | -42.49% | -13.75% | -23.88% | -41.51% | -55.70% | -28.32% | 12.14% | 11.89% | 4.37% | 23.48% | -31.93% | -0.92% | -7.61% | -38.39% | -44.44% |
| Operating Income | -7.69M | -13.93M | -10.73M | -9.39M | -6.40M | -8.13M | -14.17M | -9.97M | -30.08M | 815.00K | -1.78M | -5.41M | -37.19M | -6.57M | -2.12M | 4.77M | -1.10M | -6.44M | -4.75M | -267.22K | -8.08M | -9.37M | -2.54M | -1.70M | -2.20M | -2.90M | -3.10M | -5.40M | -2.20M | 1.30M | -400.00K | 4.20M | -4.50M | -2.20M | -3.20M | -4.90M | -4.90M |
| Operating Income Ratio | -44.40% | -49.85% | -31.90% | -31.61% | -20.41% | -31.73% | -50.42% | -37.85% | -72.39% | 1.86% | -5.37% | -19.14% | -129.81% | -26.74% | -7.55% | 12.71% | -4.15% | -32.65% | -24.05% | -1.15% | -123.98% | -187.40% | -52.54% | -21.76% | -32.84% | -54.72% | -39.24% | -47.79% | -10.68% | 5.33% | -1.94% | 18.26% | -37.82% | -10.14% | -17.39% | -43.75% | -181.48% |
| Total Other Income/Expenses | 699.00K | 164.00K | -512.00K | -8.18M | -7.11M | -845.00K | -106.00K | -53.00K | -2.35M | -1.67M | -5.71M | -3.92M | -395.00K | 348.27K | 109.77K | -174.60K | -434.73K | -199.28K | -3.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.60M | 0.00 | -2.70M | -300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.20M |
| Income Before Tax | -6.99M | -13.77M | -11.24M | -17.57M | -13.51M | -8.98M | -14.27M | -10.02M | -32.43M | -856.00K | -7.48M | -9.33M | -37.59M | -6.22M | -2.01M | 4.59M | -1.54M | -6.64M | -4.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 | -4.90M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.10M |
| Income Before Tax Ratio | -40.36% | -49.28% | -33.43% | -59.17% | -43.10% | -35.03% | -50.79% | -38.06% | -78.05% | -1.95% | -22.63% | -33.00% | -131.18% | -25.33% | -7.15% | 12.25% | -5.78% | -33.66% | -24.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6.33% | 0.00% | -23.79% | 4.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -300.00% |
| Income Tax Expense | 20.00K | -116.00K | 1.00K | 38.00K | 43.00K | 42.00K | -18.00K | 76.00K | 16.00K | 153.00K | 126.00K | 43.00K | 419.00K | 0.00 | -43.57K | 235.00K | 0.00 | 0.00 | 0.00 | 561.04K | 114.66K | 48.17K | 80.11K | 132.01K | 1.80M | 500.00K | -2.30M | 700.00K | 3.10M | 100.00K | 400.00K | 400.00K | 500.00K | 100.00K | 300.00K | 400.00K | 3.70M |
| Net Income | -4.85M | -13.66M | -11.25M | -17.61M | -13.55M | -9.02M | -14.26M | -10.10M | -32.45M | -1.01M | -7.61M | -9.37M | -37.59M | -6.22M | -1.97M | 4.36M | -1.54M | -6.64M | -4.76M | -828.26K | -8.20M | -9.42M | -2.62M | -1.83M | -4.00M | -3.40M | -800.00K | -6.10M | -5.30M | 900.00K | -800.00K | 3.80M | -5.00M | -2.30M | -3.50M | -5.30M | -8.60M |
| Net Income Ratio | -27.99% | -48.87% | -33.43% | -59.30% | -43.24% | -35.19% | -50.73% | -38.34% | -78.08% | -2.30% | -23.01% | -33.15% | -131.18% | -25.33% | -7.00% | 11.62% | -5.78% | -33.66% | -24.07% | -3.55% | -125.74% | -188.36% | -54.20% | -23.45% | -59.70% | -64.15% | -10.13% | -53.98% | -25.73% | 3.69% | -3.88% | 16.52% | -42.02% | -10.60% | -19.02% | -47.32% | -318.52% |
| EPS | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.44 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| EPS Diluted | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.40 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| Weighted Avg Shares Out | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.68M | 16.34M | 15.93M | 15.67M | 14.10M | 10.84M | 10.77M | 10.91M | 9.17M | 9.10M | 8.34M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 1.81M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
| Weighted Avg Shares Out (Dil) | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.69M | 16.34M | 15.93M | 15.69M | 14.10M | 10.84M | 10.80M | 10.91M | 9.17M | 9.10M | 8.55M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 2.00M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022
NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2022,...
7 Little-Known Stocks With Millionaire-Maker Potential
Although, on the surface, everything looks gloomy now for stocks, one point that the bears are forgetting, I would argue, is that we live in an era of unprecedented technological advancement. Never before in the world has there simultaneously been...
Global Computer Vision in Healthcare Market Report 2022: Escalating Need for Quality Inspection and Automation in Healthcare Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Computer Vision in Healthcare Market (2022-2027) by Component, Applications, End-user, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Computer Vision in Healthcare Market is estimated...
Insights on the Radiation Oncology Global Market to 2027 - Rapid Expansion of Cancer Research Centers Worldwide is Positively Influencing Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Radiation Oncology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global radiation oncology market reached a value of US$ 6.97 Billion in 2021. Looking forward, the publisher...
Global White Biotechnology Market Report 2022: Increasing demand for Biofuels and Green Chemicals Drives Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global White Biotechnology Market (2022-2027) by Product, Application, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global White Biotechnology Market is estimated to be worth USD 208...
SIMS Hospital Pedals for a Healthy Aorta
Cycle rally creates awareness and spreads hope about Aortic Disorder on Aortic Dissection Awareness Day 2022 Thiru Shekhar Deshmukh IPS, Deputy Commissioner of Police Flagged off the Cycle Rally The Institute of Cardiac and Aortic Disorders (ICAD) at SIMS hospitals,...
iCAD Customers in the U.S. and Europe Increasingly Adopting Company's Full Suite of Breast AI Technologies via Subscription Model
Flexible subscription model accelerates deployment of iCAD's Breast AI Suite, the only complete solution designed to comprehensively address today's top imaging challenges Flexible subscription model accelerates deployment of iCAD's Breast AI Suite, the only complete solution designed to comprehensively address...
After Plunging 29.6% in 4 Weeks, Here's Why the Trend Might Reverse for Icad (ICAD)
Icad (ICAD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Global Radiotherapy Market Report 2022: Rising Cancer Prevalence Worldwide to Drive Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Radiotherapy Market by Type (Product, Service), Technology (LINAC, Stereotactic LINAC, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) - Global Forecasts to 2027" report has been added to ResearchAndMarkets.com's...
iCAD, Inc. (ICAD) CEO Stacey Stevens on Q2 2022 Results - Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Tony Takazawa - Director, Investor Relations Stacey Stevens - President and Chief Executive Officer Steve Sarno - Interim Chief Financial Officer Conference Call...
Source: https://incomestatements.info
Category: Stock Reports